Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-Current Debt (2020 - 2021)

Historic Non-Current Debt for Insight Molecular Diagnostics (IMDX) over the last 2 years, with Q3 2021 value amounting to $178000.0.

  • Insight Molecular Diagnostics' Non-Current Debt fell 9138.01% to $178000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $178000.0, marking a year-over-year decrease of 9138.01%. This contributed to the annual value of $1.5 million for FY2020, which is N/A changed from last year.
  • Insight Molecular Diagnostics' Non-Current Debt amounted to $178000.0 in Q3 2021, which was down 9138.01% from $541000.0 recorded in Q2 2021.
  • Over the past 5 years, Insight Molecular Diagnostics' Non-Current Debt peaked at $2.6 million during Q2 2020, and registered a low of $178000.0 during Q3 2021.